Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 21,806 restricted stock units to 16 newly hired non-executive officers. The awards, approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan on March 16, 2025, serve as an employment inducement in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato l'assegnazione di 21.806 unità azionarie vincolate a 16 nuovi dirigenti non esecutivi. I premi, approvati dal comitato per la remunerazione e concessi nell'ambito del Piano di Induzione all'Occupazione di Ultragenyx il 16 marzo 2025, fungono da incentivo all'occupazione in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le unità azionarie vincolate prevedono un programma di maturazione di quattro anni, con il 25% delle azioni che matura annualmente all'anniversario della data di concessione, a condizione di un'occupazione continua.
Ultragenyx Pharmaceutical (NASDAQ: RARE) anunció la concesión de 21,806 unidades de acciones restringidas a 16 nuevos funcionarios no ejecutivos. Los premios, aprobados por el comité de compensación y otorgados bajo el Plan de Inducción al Empleo de Ultragenyx el 16 de marzo de 2025, sirven como un incentivo de empleo en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4). Las unidades de acciones restringidas cuentan con un cronograma de adquisición de cuatro años, con el 25% de las acciones adquiriéndose anualmente en el aniversario de la fecha de concesión, condicionado a la continuidad del empleo.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 16명의 신규 비상임 임원에게 21,806개의 제한 주식 단위를 부여했다고 발표했습니다. 이 상은 보상 위원회에 의해 승인되었으며 2025년 3월 16일에 Ultragenyx 고용 유도 계획에 따라 부여되었습니다. 이 제한 주식 단위는 Nasdaq 상장 규정 5635(c)(4)에 따라 고용 유도로 사용됩니다. 제한 주식 단위는 4년의 분배 일정을 특징으로 하며, 25%의 주식이 부여일 기념일에 매년 분배되며, 지속적인 고용에 따라 달라집니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE) a annoncé l'attribution de 21 806 unités d'actions restreintes à 16 nouveaux cadres non exécutifs. Les récompenses, approuvées par le comité de rémunération et accordées dans le cadre du Plan d'Induction à l'Emploi d'Ultragenyx le 16 mars 2025, servent d'incitation à l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les unités d'actions restreintes présentent un calendrier d'acquisition de quatre ans, avec 25 % des actions acquises annuellement à l'anniversaire de la date d'attribution, sous réserve d'un emploi continu.
Ultragenyx Pharmaceutical (NASDAQ: RARE) gab die Zuteilung von 21.806 beschränkten Aktieneinheiten an 16 neu eingestellte nicht-executive Mitarbeiter bekannt. Die Auszeichnungen, die vom Vergütungsausschuss genehmigt und im Rahmen des Ultragenyx Employment Inducement Plans am 16. März 2025 gewährt wurden, dienen als Beschäftigungsanreiz gemäß der Nasdaq-Listing-Regel 5635(c)(4). Die beschränkten Aktieneinheiten haben einen vierjährigen Vesting-Zeitplan, wobei 25 % der Aktien jährlich am Jahrestag des Gewährungsdatums fällig werden, abhängig von einer kontinuierlichen Beschäftigung.
- None.
- None.
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the company’s common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees in March 2025?
What is the vesting schedule for Ultragenyx's (RARE) March 2025 restricted stock units?
Under which plan were Ultragenyx's (RARE) March 2025 stock units granted?
What is the purpose of Ultragenyx's (RARE) March 2025 restricted stock unit grants?
